Asthma: Airway Inflammation and Reversible Obstruction

Core Idea

Asthma is a chronic airway disease characterized by reversible obstruction, bronchial hyperresponsiveness, and eosinophilic inflammation. Type 2 inflammation (Th2 cells, IL-4, IL-5) drives mast cell activation, smooth muscle contraction, and mucus production.

How It's Best Learned

Compare allergic and non-allergic asthma pathways. Study the acute asthma attack: bronchoconstriction, mucus plugging, and hypoxemia. Understand biomarkers (eosinophils, IgE) and their role in phenotyping.

Common Misconceptions

Asthma is not purely reversible—chronic inflammation can cause remodeling and fixed obstruction. Normal spirometry does not exclude asthma; bronchial provocation testing is needed for diagnosis.

Explainer

To understand asthma, start with what you already know about the respiratory system: the airways are lined with smooth muscle, mucus-secreting goblet cells, and a mucosal immune layer. In a healthy airway, these elements maintain patency and clear debris. In asthma, a misdirected immune response turns the airway into a site of chronic inflammation — and that inflammation drives obstruction through three simultaneous mechanisms: bronchoconstriction (smooth muscle contraction), mucosal edema (swelling of the airway wall), and mucus hypersecretion (goblet cell activation). Understanding all three together explains why the obstruction is partially reversible but never fully innocent.

The immunological engine of allergic asthma is Type 2 inflammation, which you encountered when studying type I hypersensitivity. In sensitized individuals, inhaled allergens activate Th2 cells, which release IL-4 and IL-13 (driving IgE production and mucus) and IL-5 (driving eosinophil survival and recruitment). Mast cells, pre-loaded with IgE from prior sensitization, degranulate immediately on allergen re-exposure, releasing histamine, leukotrienes, and prostaglandins. This early-phase response causes bronchoconstriction within minutes. Four to eight hours later, eosinophils recruited by IL-5 flood the airway mucosa, releasing major basic protein and eosinophil cationic protein — toxic granule contents that damage the epithelium and amplify inflammation. This late-phase response is responsible for prolonged obstruction and the priming of the airway for future attacks.

The concept of bronchial hyperresponsiveness explains a paradox: asthmatics bronchoconstrict in response to stimuli (cold air, exercise, irritants, viral infections) that cause no response in normal subjects. The chronically inflamed, edematous airway has altered smooth muscle reactivity and impaired neural regulation. Airway smooth muscle hypertrophies with repeated activation, and sensory nerve endings become hyperexcitable — the threshold for bronchoconstriction falls dramatically. This is why asthma severity correlates not just with acute attacks but with the degree of airway hyperresponsiveness measured on methacholine challenge: the more responsive the airway, the more provocations trigger symptoms.

Critically, the name "reversible obstruction" is partly misleading. Acute bronchoconstriction reverses with bronchodilators. But chronic, uncontrolled inflammation leads to airway remodeling — subepithelial fibrosis, smooth muscle hypertrophy, and increased vascularity — that permanently reduces airway caliber. This is why untreated or undertreated asthma can progress to fixed airflow limitation resembling COPD, even in the absence of smoking. The therapeutic implication is direct: inhaled corticosteroids target the underlying Type 2 inflammation, not just the acute bronchoconstriction, and their consistent use prevents remodeling. Short-acting bronchodilators treat symptoms; anti-inflammatory therapy treats disease. Knowing the difference between the mechanisms explains why relying on rescue inhalers alone — addressing bronchoconstriction without inflammation — allows long-term airway damage to accumulate.